FGEN Sep 2024 1.500 put
| Previous close | 0.7400 |
| Open | 0.7400 |
| Bid | 0.5000 |
| Ask | 1.0500 |
| Strike | 1.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.7400 - 0.7400 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireFibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payloadRecommended Phase 2 dose of FG-3246 was established at 2.1 mg/kg every 3 weeks in combination with enzalutamide given at the standard dose of 160 mg daily SAN FRANCISCO, May 23, 2024 (GLO
Simply Wall St.FibroGen First Quarter 2024 Earnings: Beats Expectations
FibroGen ( NASDAQ:FGEN ) First Quarter 2024 Results Key Financial Results Revenue: US$55.9m (up 55% from 1Q 2023). Net...
Insider MonkeyFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript May 6, 2024 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.33272 EPS, expectations were $-0.31. FGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
